BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence
Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San
Francisco on Thursday, January 11, 2018 at 10 a.m. PST. The presentation will include a detailed update on the Company’s clinical
development programs and corporate development efforts.
To access a live audio webcast of the presentation, please visit the Investor Relations section at
www.ziopharm.com. The webcast will be archived for 90 days.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression,
control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer
and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and
the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use
non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together
with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off,
and precisely modulate, gene expression such as IL-12 in order to improve therapeutic index. The Company's pipeline includes a
number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor
malignancies.
Contact:
David Connolly
ZIOPHARM Oncology
617-502-1881
dconnolly@ziopharm.com
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/b0b5e9d5-c4fd-4905-8feb-78c370b64f2a?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzA1MTQ0MQ==)